COMPANY
Versatope Therapeutics
Funding and NIH signals
- NIH award NIH awarded $1M (SBIR Phase II 5R44AI181242-03, continuation, notice Jun 11, 2026). NIH RePORTER 5R44AI181242-03 (Jun 11, 2026)
Evidence (1 event)
- Jun 11, 2026 · NIH RePORTER 5R44AI181242-03
Organization: VERSATOPE THERAPEUTICS, INC.; City/State: Lowell, MA; Project number: 5R44AI181242-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 999925; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine; Organization type: Domestic For-Profits
- Jun 11, 2026 · NIH RePORTER 5R44AI181242-03
Timeline
- Grant Government grant — SBIR: $999,925 (annual award, as published), announced Jun 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Grant Government grant — SBIR: $999,993 (annual award, as published), announced Nov 1, 2024. Agency: NIH/NIAID. Source: government award database. source ↗
Funding
- Government grant — SBIR: $999,925 (annual award, as published), announced Jun 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
- Government grant — SBIR: $999,993 (annual award, as published), announced Nov 1, 2024. Agency: NIH/NIAID. Source: government award database. source ↗